Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.
Ryan Sullivan, MD, associate professor, Medicine, Harvard Medical School and associate professor, Hematology/Oncology, Massachusetts General Hospital, explains how tumor infiltrating lymphocytes (TIL) could impact the melanoma treatment landscape if approved by the FDA.
0:08 | Having a therapy that's totally a different type of therapy than what we have available offers a lot of potential. One next step may be combining it with the things we already have. It may be combined with anti PD-1, anti-PD-1 plus anti CTLA4, or anti-PD-1 and LAG3. It may also be explored in earlier lines of therapy or in the refractory space.
0:40 | There's some data with other compounds that suggested that combining these types of drugs with a novel immunotherapy could be useful, even if patients had previously been treated with an anti-PD-1-based regimen. I think that's the second thing, that there may be combinations of therapies that currently are being studied, and it potentially could be a next step beyond just having TIL. The other thing is that there are a lot of ways of modifying and manipulating cells. If you’re getting a TIL harvest from a patient, it's entirely possible that there are ways to make those TIL better. You could select for tumor antigen specific T cells. You can select or treat those cells in a way to make them a better TIL. There's data that's been generated from a lot of labs in this space trying to come up with a better way of not necessarily giving TIL, but a better product that they can generate just by doing certain modifications after the TIL is harvested and before patients receive the TIL.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More